ArticleEndocrine oncology (Bristol, England)2021
Serum osteopontin can improve papillary thyroid cancer risk assessment of Bethesda III thyroid nodules: a preliminary study.
T U Kars et al.PubMed ↗Full text ↗Publisher ↗
No numbers read from the abstract.